Items where Author is "Taubert, H."

Article

Stoehr, C. G. and Stoehr, R. and Wenners, A. and Hartmann, A. and Bertz, S. and Spath, V. and Walter, B. and Junker, K. and Moch, H. and Hinze, R. and Denzinger, S. and Bond, E. E. and Bond, G. L. and Bluemke, K. and Weigelt, K. and Lieb, V. and Nolte, E. and Fornara, P. and Wullich, B. and Taubert, H. and Wach, S. (2016) Homozygous G/G variant of SNP309 in the human MDM2 gene is associated with earlier tumor onset in Caucasian female renal cell carcinoma patients. ONCOGENESIS, 5: e205. ISSN 2157-9024

Conference or Workshop Item

Erlmeier, F. and Kluemper, N. and Landgraf, L. and Strissel, P. and Strick, R. and Sikic, D. and Taubert, H. and Wach, S. and Geppert, C. and Bahlinger, V and Breyer, J. and Ritter, M. and Bolenz, C. and Roghmann, F. and Erben, P. and Schwamborn, K. and Wirtz, R. and Horn, T. and Wullich, B. and Hoelzel, M. and Hartmann, A. and Gschwend, J. and Weichert, W. and Eckstein, M. (2023) Spatial immunephenotypes of distant metastases but not matched primary urothelial carcinomas predict response to immune checkpoint inhibition. In: EAU23 - 38th Annual EAU Congress, 10-13 March 2023, Milan, Italy.

Wullweber, A. and Strick, R. and Lange, F. and Sikic, D. and Taubert, H. and Wach, S. and Wullich, B. and Bertz, S. and Weyerer, V. and Stoehr, R. and Breyer, J. and Burger, M. and Hartmann, A. and Strissel, P. and Eckstein, M. (2021) Bladder tumor subtype commitment occurs in carcinoma in-situ driven by key signaling pathways including ECM remodeling. In: EAU21, 8. - 12. July 2021, Virtual.

Weyerer, V. and Geppert, C. and Bertz, S. and Taubert, H. and Breyer, J. and Bolenz, C. and Erben, P. and Wach, S. and Sikic, D. and Kunath, F. and Wullich, B. and Hartmann, A. and Eckstein, M. (2020) Divergent immunobiological correlates of FDA-/EMA-approved PD-L1 assays and scoring algorithms in muscle-invasive bladder cancer. In: International Bladder Cancer Network (IBCN), October 17, 2020.

Other

Jarczyk, J. and Wirtz, R. and Roghmann, F. and Juette, H. and Kriegmair, M. C. and Worst, T. S. and Sikic, D. and Wach, S. and Taubert, H. and Wullich, B. and Weyerer, V. and Stoehr, R. and Zengerling, F. and Bolenz, C. and Breyer, J. and Burger, M. and Porubsky, S. and Hartmann, A. and Erben, P. and Eckstein, M. (2019) Efficacy of anti-PD(L)1 treatment in patients with metastatic urothelial cancer based on mRNA- and protein- based PD-L1 determination: Results from the multicentric, retrospective FOsMIC trial. OXFORD UNIV PRESS, OXFORD.

Roghmann, F. and Wirtz, R. and Jarczyk, J. and Kriegmair, M. C. and Worst, T. S. and Sikic, D. and Wach, S. and Taubert, H. and Wullich, B. and Weyerer, V. and Stoehr, R. and Zengerling, F. and Bolenz, C. and Breyer, J. and Burger, M. and Porubsky, S. and Hartmann, A. and Erben, P. and Eckstein, M. and Juette, H. (2019) Prognostic role of FGFR Mutations and FGFR mRNA expression in metastatic urothelial cancer treated with anti-PD(L1) inhibitors in first and second-line setting. OXFORD UNIV PRESS, OXFORD.

Eckstein, M. and Strissel, P. and Pfannstiel, C. and Chiappinelli, K. and Sikic, D. and Wach, S. and Taubert, H. and Wullich, B. and Keck, B. and Wirtz, R. and Breyer, J. and Burger, M. and Otto, W. and Fuhrich, N. and Geppert, C. and Weyerer, V. and Bertz, S. and Stoehr, R. and Erlmeier, F. and Hartmann, A. and Strick, R. (2019) Tumour immune microenvironment drives prognostic relevance correlating with bladder cancer subtypes. SPRINGER, NEW YORK.

Eckstein, M. and Wirtz, R. and Pfannstil, C. and Wach, S. and Stoehr, R. and Breyer, J. and Erlmeier, F. and Guenes, C. and Nitschke, K. and Weichert, W. and Otto, W. and Keck, B. and Eidt, S. and Burger, M. and Taubert, H. and Wullich, B. and Bolenz, C. and Hartmann, A. and Erben, P. (2018) A multicenter comparison of PD-L1 protein and mRNA expression in urothelial bladder cancer by immunohistochemistry and RT-qPCR (Checkpoint-Typer(C)): A round robin test by the BRIDGE-Consortium Germany. KARGER, BASEL.